Correction: SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection

Jolein Mijnes; Janina Tiedemann; Julian Eschenbruch; Janina Gasthaus; Sarah Bringezu; Dirk Bauerschlag; Nicolai Maass; Norbert Arnold; Jörg Weimer; Tobias Anzeneder; Peter A. Fasching; Matthias Rübner; Benjamin Bruno; Uwe Heindrichs; Jennifer Freres; Hanna Schulz; Ralf-Dieter Hilgers; Nadina Ortiz-Brüchle; Sonja von Serenyi; Ruth Knüchel; Vera Kloten; Edgar Dahl

doi:10.18632/oncotarget.27685

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection

PDF | How to cite

Oncotarget. 2020; 11:2958-2958. https://doi.org/10.18632/oncotarget.27685

Metrics: PDF 1022 views | ?

Jolein Mijnes¹, Janina Tiedemann¹, Julian Eschenbruch¹, Janina Gasthaus¹, Sarah Bringezu¹, Dirk Bauerschlag³, Nicolai Maass³, Norbert Arnold^3,6, Jörg Weimer³, Tobias Anzeneder⁴, Peter A. Fasching⁵, Matthias Rübner⁵, Benjamin Bruno⁷, Uwe Heindrichs⁷, Jennifer Freres⁷, Hanna Schulz¹, Ralf-Dieter Hilgers⁸, Nadina Ortiz-Brüchle¹, Sonja von Serenyi¹, Ruth Knüchel¹, Vera Kloten^1,9,* and Edgar Dahl^1,2,*

¹ Molecular Oncology Group, Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany
² RWTH centralized Biomaterial Bank (RWTH cBMB) at the Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany
³ Department of Gynecology and Obstetrics, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany
⁴ Patients' Tumor Bank of Hope (PATH-Biobank) Foundation, München, Germany
⁵ Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
⁶ Institute of Clinical Molecular Biology, University Medical Centre Schleswig-Holstein, Campus Kiel, Christian-Albrechts- University, Kiel, Germany
⁷ Department of Gynecology and Obstetrics Luisenhospital, Aachen, Germany
⁸ Institute of Medical Statistics, University Hospital RWTH Aachen, Aachen, Germany
⁹ Current address: Bayer AG, Pharmaceuticals Division, Biomarker Research, Wuppertal, Germany
^* Share equal senior authorship

Published: July 28, 2020

This article has been corrected: The Grant section information has been updated with the following logos:

Original article: Oncotarget. 2019; 10:6494–6508. DOI: https://doi.org/10.18632/oncotarget.27303.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27685

Publication Alerts

Corrections:

Correction: SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection